Early-Stage Formulation Considerations.

Area of Science:

• Pharmaceutical Development
• Drug Discovery
• Preclinical Research

Background:

• Drug candidates, including new chemical entities (NCEs) or new molecular entities (NMEs), require suitable vehicles for early-stage testing.
• The ideal vehicle should be biologically inert, ensuring it does not interfere with the assessment of the active pharmaceutical ingredient's (API) activity or toxicity.
• High attrition rates in drug discovery necessitate efficient and cost-effective methods for early development.

Purpose of the Study:

• To provide guidance on developing early-stage test articles for in vitro and in vivo evaluations.
• To emphasize the importance of selecting appropriate vehicles that do not confound API effects.
• To focus on the practical considerations of speed and cost in early drug development.

Main Methods:

• Guidance is provided for the development of test articles, which are drug products containing APIs.
• The focus is on preparations for initial in vitro and/or in vivo evaluations.
• This guidance is distinct from the development of formulations intended for clinical trials.

Main Results:

• The chapter outlines strategies for creating early-stage drug test articles.
• It highlights the critical need for vehicles that do not introduce confounding biological activity or toxicity.
• The development process prioritizes speed and cost-efficiency.

Conclusions:

• Effective development of early-stage test articles is crucial for accurate preclinical drug assessment.
• Vehicle selection is paramount to avoid masking or altering the inherent properties of the API.
• The guidance supports efficient and cost-effective early drug development, prioritizing initial evaluations over extensive formulation characterization.